Vericel Corporation (VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

No competitor list for this company yet.

• 2/26/2026NEUTRAL
  Vericel (VCEL) Q4 2025 Earnings Call Transcript

  Biotechnology firm Vericel (VCEL) held its fourth-quarter 2025 earnings conference call. While specific details from the transcript are not yet available, this event is crucial for investors monitoring the company's financial performance and future outlook. Earnings calls are key moments to assess operational health, revenues, profit margins, and management's guidance. The immediate lack of information prevents an in-depth analysis, but the market will keenly await the data release to understand the impact on key products like MACI and Epicel. Investors should remain vigilant for subsequent communications that could influence the stock's valuation.